| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2019.10.053 |
| P698 | PubMed publication ID | 31735505 |
| P50 | author | Alicia M Fry | Q87077992 |
| Melissa A Rolfes | Q87793670 | ||
| Mark G. Thompson | Q91141663 | ||
| P2093 | author name string | Sarah Spencer | |
| Eduardo Azziz-Baumgartner | |||
| William Davis | |||
| Manish M Patel | |||
| Angela P Campbell | |||
| Min Z Levine | |||
| Lauren Beacham | |||
| Kathryn Lafond | |||
| P2860 | cites work | Systems vaccinology informs influenza vaccine immunogenicity | Q26700003 |
| Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis | Q26751854 | ||
| Evolution of the immune system in humans from infancy to old age | Q26772107 | ||
| Influenza Virus Neuraminidases with Reduced Enzymatic Activity That Avidly Bind Sialic Acid Receptors | Q27673691 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Social contacts and mixing patterns relevant to the spread of infectious diseases | Q28755323 | ||
| Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. | Q30356623 | ||
| Vaccine recommendations for children and youth for the 2017/2018 influenza season. | Q51409632 | ||
| Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. | Q52598059 | ||
| The functional growth and development of the lung during the first year of life | Q54591515 | ||
| Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes | Q56987878 | ||
| Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children | Q56990918 | ||
| Immunology and efficacy of MF59-adjuvanted vaccines | Q57094222 | ||
| Immunogenicity and Reactogenicity of 1 versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine‐Naive 5–8‐Year‐Old Children | Q57385003 | ||
| Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal | Q57466752 | ||
| Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season | Q58709341 | ||
| Influenza Immunization in Pregnancy — Antibody Responses in Mothers and Infants | Q58823336 | ||
| Influenza Vaccine in Young Children | Q61856944 | ||
| Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza | Q71120792 | ||
| Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children | Q72389002 | ||
| Influenza vaccine for young children: two doses are better than one | Q79396295 | ||
| Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? | Q80208528 | ||
| More on influenza vaccine in young children | Q84470306 | ||
| Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study | Q84927314 | ||
| Oil-in-water emulsion adjuvant with influenza vaccine in young children | Q85087747 | ||
| How do we best prevent influenza in young children? | Q88310213 | ||
| Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization | Q30361644 | ||
| Molecular and cellular signatures of human vaccine adjuvants. | Q30370898 | ||
| Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine | Q30375872 | ||
| Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. | Q30376757 | ||
| A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. | Q30383269 | ||
| Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands | Q30398281 | ||
| MF59 adjuvant: the best insurance against influenza strain diversity | Q30402018 | ||
| MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines | Q30403361 | ||
| Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children | Q30409092 | ||
| Serologic assays for influenza surveillance, diagnosis and vaccine evaluation | Q34194336 | ||
| Fetal and Postnatal Development of the Lung | Q34257525 | ||
| The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children | Q34467468 | ||
| Does raising type 1 error rate improve power to detect interactions in linear regression models? A simulation study | Q34970550 | ||
| Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children | Q35167127 | ||
| Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. | Q35611863 | ||
| Power for tests of interaction: effect of raising the Type I error rate | Q35874880 | ||
| Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood | Q36607400 | ||
| Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age. | Q36977899 | ||
| Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses | Q37568360 | ||
| Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis | Q37955413 | ||
| Influenza burden in febrile infants and young children in a pediatric emergency department. | Q38464259 | ||
| Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children | Q39308116 | ||
| Molecular mechanisms of variation in influenza viruses | Q40102702 | ||
| Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza hospitalizations - Latin America, 2013. | Q40146222 | ||
| Understanding immune responses to the influenza vaccine | Q40421703 | ||
| From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--I | Q41516459 | ||
| Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses | Q41865771 | ||
| Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children | Q42189522 | ||
| Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. | Q42205469 | ||
| The burden of influenza hospitalizations in infants from 2003 to 2012, United States | Q42234781 | ||
| MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination | Q43258765 | ||
| Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children | Q43963300 | ||
| Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant | Q44543899 | ||
| Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary | Q45056829 | ||
| Influenza virus infections in infants | Q45759256 | ||
| The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells | Q46662919 | ||
| Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States | Q47549841 | ||
| The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines? | Q47564262 | ||
| MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico | Q50024815 | ||
| What Have We Learned About Influenza Deaths in Children and How Can We Do Better? | Q50026192 | ||
| Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. | Q50690322 | ||
| P433 | issue | 3 | |
| P921 | main subject | influenza vaccine | Q383260 |
| P304 | page(s) | 608-619 | |
| P577 | publication date | 2019-11-15 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis | |
| P478 | volume | 38 |
| Q94602411 | Recent advances in influenza vaccines |
| Q101163380 | Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies |
Search more.